Relay Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Relay Therapeutics, Inc. on September 9, 2024. The filing discloses interim clinical data for the Company's lead candidate, RLY-2608, and updates on the regulatory path for lirafugratinib (RLY-4008). The data cut-off date for the clinical results was August 12, 2024.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial progress and regulatory interactions.
Material Changes and Clinical Data
The primary material event is the announcement of interim data from the ReDiscover Trial for RLY-2608, an allosteric, pan-mutant, isoform-selective inhibitor of PI3Kα.
- Study Population: 118 patients enrolled in the RLY-2608 and fulvestrant combination arm. Analysis focused on 64 patients at the Recommended Phase 2 Dose (RP2D) of 600mg twice daily.
- Efficacy (52 evaluable patients without PTEN/AKT co-mutations):
- Median Progression-Free Survival (PFS): 9.2 months (all mutations) and 10.3 months (kinase mutations).
- Clinical Benefit Rate (CBR): 57% (defined as complete response, partial response, or stable disease ≥24 weeks).
- Objective Response Rate (ORR): 33% overall; 53% among patients with kinase mutations.
- Tumor Reductions: 73% of patients experienced tumor reductions.
- Safety and Tolerability:
- Generally well tolerated with mostly low-grade, manageable adverse events.
- 95% median dose intensity achieved.
- Only 25% of patients experienced Grade 3 treatment-related adverse events (TRAEs); no Grade 4-5 TRAEs.
- Hyperglycemia was predominantly Grade 1; only one patient experienced Grade 3 hyperglycemia.
Outlook, Guidance, and Regulatory Updates
RLY-2608: The Company is progressing two front-line triplet regimens combining RLY-2608 and fulvestrant with either ribociclib or Pfizer's atirmociclib.
Lirafugratinib (RLY-4008): Following a meeting with the FDA, the Company plans to first file a New Drug Application (NDA) for cholangiocarcinoma, followed by a tumor-agnostic supplemental NDA for FGFR2 fusions. Updated data will be presented at the AACR-NCI-EORTC conference in October 2024. The Company intends to seek a global commercialization partner for this asset to maintain focus on its broader portfolio.
Risks: The filing includes standard forward-looking statement disclaimers regarding clinical trial outcomes, regulatory approvals, and the potential for interim data to change as more information becomes available.
Investor Verification Checklist
- Verify the final, audited clinical data for RLY-2608 once the full study results are available, as interim data may change.
- Monitor the timeline and outcome of the FDA's review of the lirafugratinib NDA for cholangiocarcinoma.
- Track the progress of the Company's search for a global commercialization partner for lirafugratinib.
- Review the Company's most recent Form 10-K or 10-Q for updated cash runway and liquidity positions, as this 8-K does not contain financial statements.
- Confirm the enrollment and data cut-off dates for the ongoing triplet regimen trials with ribociclib and atirmociclib.